CBBC has supported hundreds of companies like yours to enter the Chinese market, demystifying the challenges and optimising their strategies. To read more about how we have guided our clients towards success in China, please choose a case study from the selection below. Our client success stories give a first-hand perspective on our client centric approach and the powerful impact from working with CBBC.
Established in 1955, ADAM Architecture is a UK-based classical architecture and contextual urban design company which is well-known for its design work. The directors - leading practitioners, Robert Adam, Nigel Anderson, Robbie Kerr, Hugh Petter, and George Saumarez Smith - bring their specialist knowledge of traditional and classical design to their projects; pioneering the application of local contextual knowledge to the design of new areas.
Ayton Global Research is a global research organisation that specialises in conducting online research for brand owners, contract manufacturers, cosmetic consultants and marketing agents. Its research spans all FMCG sectors. Ayton Global Research's team of study managers, regulatory advisors and distribution specialists ensure their clients can make some powerful advertising claims that are completely compliant in all global markets, including China. The company's specialism is in-home consumer studies.
Invest Northern Ireland is part of the Department for the Economy of Northern Ireland and provides strong government support for businesses by effectively delivering the Government's economic development strategies. As the regional business development agency, Invest NI's goal is to grow the local economy by helping new and existing businesses to compete internationally and attracting new investment to Northern Ireland.
Teledyne e2v designs and manufactures critical products for radiotherapy systems for the treatment of cancer. These products are used in approximately 90% of the radiotherapy systems installed in hospitals and cancer centres worldwide, and have been integrated into multiple new radiotherapy platforms.
